Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : HK inno.N
Deal Size : $56.0 million
Deal Type : Licensing Agreement
Sciwind Biosciences & HK inno.N ink $56 M Deal to Treat Metabolic Diseases in Korea
Details : HK inno.N gains exclusive rights for XW003 (ecnoglutide), a GLP-1 analog, in Korea; Sciwind retains rights in other global markets.
Brand Name : XW003
Molecule Type : Peptide
Upfront Cash : Undisclosed
May 07, 2024
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : HK inno.N
Deal Size : $56.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sciwind Biosciences Announces Positive Phase 1 Trial Results of XW004
Details : XW004 (ecnoglutide) is a long-acting, cAMP signaling biased, glucagon-like peptide-1 (GLP-1) analog. It is under phase 1 clinical development for the treatment of type 2 diabetes and obesity.
Brand Name : XW004
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 23, 2024
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sciwind Announces Positive Phase 3 Results for Ecnoglutide in Type 2 Diabetes
Details : XW003 (ecnoglutide) is a long-acting GLP-1 analogue in phase 3 trials for improved biological activity in treating type 2 diabetes.
Brand Name : XW003
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 02, 2024
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : XW003 (ecnoglutide) is a novel, biased long-acting GLP-1 peptide analogue optimized for improved biological activity. GLP-1 analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for ...
Brand Name : XW003
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 30, 2023
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : XW003
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : XW003 is a novel, biased long-lasting GLP-1 peptide analogue optimized for improved biological activity and once weekly dosing. GLP-1 analogs are effective tools in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatmen...
Brand Name : XW003
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 27, 2022
Lead Product(s) : XW003
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : XW014
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : XW014, a novel oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist in development for the treatment of obesity and type 2 diabetes. XW014 is easier to manufacture than GLP-1 peptide drugs and readily bioavailable after oral dosing.
Brand Name : XW014
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 09, 2022
Lead Product(s) : XW014
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : After 14 weeks of treatment, participants receiving 1.8 mg and 2.4 mg XW003 (ecnoglutide) achieved statistically significant mean body weight loss of 8.32 kg (9.6%) and 7.27 kg (9.0%), respectively, compared to 0.62 kg (0.9%) for those receiving placebo ...
Brand Name : XW003
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 08, 2022
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : At week 20, participants receiving 0.4 mg, 0.8 mg, and 1.2 mg XW003 (ecnoglutide) had statistically significant HbA1c reductions from baseline of 1.8%, 1.9% and 2.4%, respectively, compared to 0.5% in participants receiving placebo (P < 0.0001).
Brand Name : XW003
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 02, 2022
Lead Product(s) : Ecnoglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : XW003,XW017
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : XW003 is a novel, biased long-lasting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing.
Brand Name : XW003
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 08, 2022
Lead Product(s) : XW003,XW017
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ecnoglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : XW004 is an oral tablet formulation of Ecnoglutide, a novel long-lasting GLP-1 peptide analogue under development for the treatment of obesity, type 2 diabetes and NASH.
Brand Name : XW004
Molecule Type : Peptide
Upfront Cash : Not Applicable
April 13, 2022
Lead Product(s) : Ecnoglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?